The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
How integration helps overcome common outsourcing inefficiencies: Expert insight series
Go inside Accelerator™ Drug Development to discover how an integrated outsourcing model helps overcome inefficiencies caused by fragmentation, enabling development teams to move faster and make more informed decisions.
Drug development programs can experience delays when clinical research, manufacturing, supply chain, and other functions are managed across disconnected partners. An integrated outsourcing model brings these capabilities together, improving data flow, reducing handoffs, and providing a more complete view of program progress. With shared timelines and centralized risk management, teams can identify challenges earlier, make informed decisions faster, and proactively mitigate issues before they affect key milestones.
In this video, Shauna Nolan, Director, CMC Portfolio at Thermo Fisher Scientific, explains how integrated project management further strengthens this connectivity. As an example, she showcases how Thermo Fisher’s regional CMC portfolio management teams work closely with clinical research and operational teams to anticipate how changes in areas such as patient enrollment, dosing strategies, or clinical plans could affect downstream activities. Digital tools—including cloud-standardized client workspaces, integrated program timelines, centralized risk registers, and formal documentation such as meeting minutes and action trackers—also reduce administrative burden, allowing teams to focus more of their time on proactive problem-solving.
The greatest value of connectivity is the ability to respond quickly to change
When critical program factors such as clinical results, regulatory expectations, or development strategies change suddenly, an integrated team can rapidly assess downstream implications and provide sponsors with the information needed to determine the best path forward. Open, transparent communication about both immediate needs and long-term strategy further strengthens this approach, enabling decisions that support today’s priorities without compromising future phases of drug development.
Learn how an integrated CDMO and CRO model can help drug developers:
- Reduce team fragmentation and enable faster decision-making
- Identify risks early on and develop proactive mitigation strategies
- Improve agility to quickly respond to changing program needs
- Leverage digital tools to help improve oversight across teams
- Reduce rework and support the long-term success of a program
Expert:
Shauna Nolan, Director, CMC Portfolio at Thermo Fisher Scientific
Shauna Nolan is Director, CMC Portfolio Management at Thermo Fisher Scientific, helping connect teams and priorities across manufacturing, clinical research, and clinical supply. Her work focuses on integrated program oversight, cross-functional collaboration, and proactive risk management, helping teams identify potential impacts early, coordinate mitigation strategies, and maintain visibility across critical program milestones.
This is part of a larger series, “Expert Perspective: Inside Accelerator™ Drug Development.” Watch the full video featuring seven industry-leading, cross-functional experts here.